Contrasting Effects of Diclofenac and Ibuprofen on Active Imatinib Uptake Into Leukaemic Cells
Contrasting Effects of Diclofenac and Ibuprofen on Active Imatinib Uptake Into Leukaemic Cells
Br J Cancer. 2012 May 1;1061772-1778, J Wang, TP Hughes,
Contrasting Effects of Diclofenac and Ibuprofen on Active Imatinib Uptake Into Leukaemic Cells
Br J Cancer. 2012 May 1;1061772-1778, J Wang, TP Hughes,
Thanks to Andrew Schorr of Patient Power who produced the following video interview with Brian Druker MD.
'Results from the ongoing Phase 2 PACE trial of ponatinib reported in June at this year’s annual meeting of the American Society of Clinical Oncology showed that 54 percent of chronic-phase CML patients who were resistant or intolerant to tyrosine kinase inhibitor therapy in the trial, including 70 percent of patients who have a T315I mutation, achieved a major cytogenetic response (MCyR) – the primary endpoint of the PACE trial. Thirty percent of these same patients achieved a major molecular response (MMR). MMR is the primary endpoint of ARIAD’s Phase 3 EPIC trial comparing ponatinib to imatinib that is now underway in newly diagnosed chronic-phase CML patients.
New Data Confirm Safety of Stopping Imatinib in Leukemia
IMNG Medical Media. 2012 Jun 26, S Freeman
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 27, 2012--
Leukemia. 2012 Mar 26. doi: 10.1038/leu.2012.85. [Epub ahead of print]
Leukemia advance online publication
15 June 2012; doi: 10.1038/leu.2012.134
New Data Confirm Safety of Stopping Imatinib in Leukemia
IMNG Medical Media. 2012 Jun 26, S Freeman
Ho-Young Yhim, Na-Ri Lee, Eun-Kee Song, Chang-Yeol Yim, So Yeon Jeon, Seunghwan Shin, Jeong-A Kim, Hee Sun Kim, Eun Hae Cho, Jae-Yong Kwak
Division of Hematology/Oncology, Department of Internal Medicine, Republic of Korea.
PACE: Robust and Durable Antileukemic Responses With Ponatinib in Patients With Heavily Pretreated, Refractory CML or Ph+ ALL
Posting Date: June 06, 2012
Updated analysis of PACE: single-arm phase II trial[1]
Summary of Key Conclusions:
www.clinicaloptions.com/Oncology/Conference>